GlassScriptPhysician profile
Jennifer Greenblatt
NPI 1447562251
$8,352.17
in general payments reported to CMS, 2019-2025
58 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,363 · 2020: $410 · 2021: $284 · 2022: $619 · 2023: $1,581 · 2024: $2,489 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,675.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,535.79 | 2019-2025 | |
| Novo Nordisk INC | $1,151.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $731.80 | 2019-2025 | |
| Lilly USA, LLC | $542.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $435.56 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $383.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Axsome Therapeutics, INC. | $363.23 | 2023-2025 | Sunosi, Auvelity |
| Abbott Laboratories | $314.07 | 2021-2025 | Freestyle Libre 3, Octrode, Proclaim |
| Astellas Pharma US INC | $268.79 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $207.50 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $198.27 | 2022 | |
| Amgen INC. | $195.17 | 2019-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $157.42 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $147.52 | 2023-2025 | Dexcom G6 Transmitter |
| Vifor Pharma, INC. | $124.40 | 2020 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Greenblatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.